Mises Wire
Author:
Timothy D. Terrell
Online Publish Date:
In this article by economist Jeffrey Sachs, pharmaceutical company Gilead is taken to task for selling its hepatitis C cure, Sofosbuvir (sold as Sovaldi), at a price of $84,000 per course of treatment. Sachs says that the actual production cost of Sofosbuvir is about $100. Sachs says that Gilead is “bilking the taxpayer” by charging the government